Investigating cancer vulnerabilities linked to specific chromatin remodeling proteins
Cancer-specific dependencies within the NuRD chromatin remodeler complex: new targets and chemical tools
This study is looking at how certain proteins can be used to develop new treatments for cancers like neuroblastoma and multiple myeloma, with the hope of finding better ways to help patients by targeting the weaknesses of cancer cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11004640 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain proteins involved in chromatin remodeling, specifically HDAC1 and HDAC2, can be targeted to treat specific types of cancer, such as neuroblastoma and multiple myeloma. By exploring the relationship between these proteins and chromosomal deletions, the research aims to identify new therapeutic strategies that exploit the unique vulnerabilities of cancer cells. The approach includes advanced techniques like CRISPR/Cas9 gene editing to disrupt these proteins and assess their impact on cancer cell survival. Patients may benefit from new targeted therapies that arise from these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with neuroblastoma or multiple myeloma, particularly those with specific genetic profiles related to HDAC1 or HDAC2.
Not a fit: Patients with cancers not related to neuroblastoma or multiple myeloma, or those without the relevant chromosomal deletions, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted cancer therapies that improve survival rates for patients with neuroblastoma and multiple myeloma.
How similar studies have performed: Previous research has shown promise in targeting chromatin remodeling proteins for cancer treatment, indicating that this approach may lead to significant advancements in therapy.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Erb, Michael a — Scripps Research Institute, the
- Study coordinator: Erb, Michael a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.